Author
Beginning Oct. 1, 2025, all applicants for commercial licenses of patents owned by the U.S. National Institutes of Health (NIH) are required to submit an Access Plan outlining how they will promote patient access to…
Beginning Oct. 1, 2025, all applicants for commercial licenses of patents owned by the U.S. National Institutes of Health (NIH) are required to submit an Access Plan outlining how they will promote patient access to…
This summer, the Center for Advanced Studies in Bioscience Innovation Law (CeBIL) at University of Copenhagen assumed stewardship and maintenance of the Patent Pledge Database created by Professor Jorge Contreras.
By Jorge L. Contreras On July 2, 2024, the High Court of the United Kingdom issued a decision in Moderna’s mRNA vaccine patent litigation against Pfizer and BioNTech. As I previously discussed in October of…
This post explains why Moderna’s cynical attempt to take back its COVID-19 vaccine patent pledge should fail.
On August 2, Senator Thom Tillis introduced a bill that, if enacted into law, would reverse the Myriad decision and a decade of subsequent developments.
The NIH, which funded much of Moderna’s research on the COVID-19 vaccine, should be assertive in exerting control over the results of this research.
The ACLU mounted an unprecedented challenge the entire practice of gene patenting in America. And, against the odds, they won.
An explanation of the WTO waiver of COVID-19 intellectual property, what the U.S. declaration of support means, and likely effects of the waiver.
Scientific research is now effectively prohibited by the majority of genealogy websites’ terms of use.
